MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-29-2024
PetIQ Accounts Receivables 2011-2025 | PETQ
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables PetIQ
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 143 M | 118 M | 114 M | 103 M | 71.4 M | 45 M | 21.8 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 143 M | 21.8 M | 87.9 M |
Quarterly Accounts Receivables PetIQ
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 152 M | - | 125 M | 169 M | 179 M | 114 M | 124 M | 160 M | 175 M | 103 M | 103 M | 103 M | 103 M | 71.4 M | 71.4 M | 71.4 M | 71.4 M | 45 M | 45 M | 45 M | 45 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 17.2 M | 17.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 179 M | 17.2 M | 84.5 M |
Accounts Receivables of other stocks in the Drug manufacturers industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Canopy Growth Corporation
CGC
|
47.5 M | $ 1.74 | - | $ 187 M |  Canada |
 |
Alimera Sciences
ALIM
|
34.5 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
47.7 M | $ 0.76 | - | $ 54 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
68.8 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
160 K | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.05 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
3.39 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
921 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
1.26 M | - | - | $ 50.1 M | USA |
 |
Organogenesis Holdings
ORGO
|
110 M | $ 4.82 | - | $ 635 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
72.4 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
387 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
191 M | $ 11.41 | - | $ 584 M | USA |
 |
Pacira BioSciences
PCRX
|
113 M | $ 26.29 | - | $ 1.22 B | USA |
 |
Evoke Pharma
EVOK
|
673 K | $ 10.95 | - | $ 36.6 M | USA |
 |
Athenex
ATNX
|
27.9 M | - | -23.39 % | $ 1.76 M | USA |
 |
Rockwell Medical
RMTI
|
10.9 M | $ 0.92 | - | $ 21.5 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
34.1 M | $ 21.36 | - | $ 2.03 B |  France |
 |
Sonoma Pharmaceuticals
SNOA
|
2.23 M | $ 3.59 | - | $ 4.46 M | USA |
 |
Evolus
EOLS
|
47.7 M | $ 7.04 | 1.88 % | $ 437 M | USA |
 |
Harrow Health
HROW
|
15.1 M | $ 47.06 | - | $ 1.53 B | USA |
 |
China Pharma Holdings
CPHI
|
232 K | $ 1.55 | -0.38 % | $ 27.1 M |  China |
 |
Veru
VERU
|
3.96 M | $ 2.42 | - | $ 326 M | USA |
 |
Bausch Health Companies
BHC
|
2 B | $ 6.92 | - | $ 2.53 B | Canada |
 |
Lannett Company
LCI
|
56.2 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
11.7 M | $ 2.53 | 1.61 % | $ 35.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
65.4 K | - | - | $ 193 M | Canada |
 |
Relmada Therapeutics
RLMD
|
512 K | $ 4.06 | - | $ 122 M | USA |
 |
Jupiter Wellness
JUPW
|
512 K | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
642 M | $ 13.14 | - | $ 1.81 B | USA |
 |
ProPhase Labs
PRPH
|
37.1 M | $ 0.11 | - | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
20.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
16.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
19.9 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
634 K | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
622 K | $ 1.2 | - | $ 5.18 M | USA |
 |
SCYNEXIS
SCYX
|
2.1 M | $ 0.65 | - | $ 31.1 M | USA |
 |
Tilray
TLRY
|
86.2 M | $ 12.15 | - | $ 7.51 B | Canada |
 |
TherapeuticsMD
TXMD
|
32.4 M | $ 1.75 | - | $ 18.3 M | USA |
 |
Zomedica Corp.
ZOM
|
1.2 M | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
3.24 B | $ 11.65 | - | $ 14.1 B | USA |